Skip to main content
SpringerLink
Log in
Book cover

Monoamine Oxidase Enzymes pp 121–138Cite as

MAO inhibitors in mental disease: their current status

  • Chapter

Part of the book series: Journal of Neural Transmission ((NEURAL SUPPL,volume 23))

Summary

Available MAOIs seem to be mainly indicated for the heterogeneous group of patients with depressive syndromes. Although groups of patients with all the recognized major subtypes of depression (including “endogenous depression”) probably respond in varying degrees, MAOIs appear to be particularly indicated for out-patients with “neurotic depression“ complicated by panic disorder or hysteroid dysphoria, which involves repeated episodes of depressed mood in response to feeling rejected. MAOIs can also be effective in several anxiety syndromes, in particular panic disorder. Other reports have claimed success in a variety of other syndromes including bulimia, anorexia nervosa, obsessive-compulsive neurosis, atypical facial pain and some other types of chronic pain, childhood attention deficit disorder and delusions of infestation by parasites. The nature of any underlying personality disorder is an important response variable and the assessment of personality should be encouraged in further studies. The development of new drugs raises the prospect of a range of MAOIs targeted at specific patient populations.

Tranylcypromine also merits further investigation as clinical experience suggests that it can produce a dramatic response in some patients with phenelzine-resistant disorders. This may be due, at least in part, to its amphetamine-like effects

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aarons SF, Mann JJ, Frances A, Kocsis J, Young RC (1984) Antidepressant effect of L-deprenyl: relative contribution of MAO-A versus MAO-B inhibition. Abstract, collegium international, neuro-psychopharmaco-logium, 14th C.I.N.P. congress, Florence, June 1984

    Google Scholar 

  • Akiskal HS (1983) Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiat 140: 11–20

    PubMed  CAS  Google Scholar 

  • Ananth J, Luchins D (1977) A review of combined tricyclic and MAOI therapy. Comp Psychiat 18: 221–230

    Article  CAS  Google Scholar 

  • Ansseau M, Kupfer DJ, Reynolds CF (1985) Internight variability of REM latency in major depression: implications for the use of REM latency as a biological correlate. Biol Psychiat 20: 489–505

    Article  PubMed  CAS  Google Scholar 

  • Baldessarini RJ (1984) Treatment of depression by altering monoamine metabolism: precursors and metabolic inhibitors. Psychopharmacol Bull 20: 224–239

    PubMed  CAS  Google Scholar 

  • Baron M, Gruen R, Asnis L, Lord S (1985) Familial transmission of schizotypal and borderline personality disorders. Am J Psychiat 142: 927–934

    PubMed  CAS  Google Scholar 

  • Cadoret RJ, O’Gorman TW, Troughton E, Heywood E (1985) Alcoholism and antisocial personality. Interrelationships, genetic and environmental factors. Arch Gen Psychiat 42: 161–167

    Article  PubMed  CAS  Google Scholar 

  • Callingham BA (1986) Some aspects of monoamine oxidase pharmacology. Cell Biochem Funct 4: 99–108

    Article  PubMed  CAS  Google Scholar 

  • Casacchia M, Carolei A, Barba C (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 17: 122–125

    Article  PubMed  CAS  Google Scholar 

  • Charney DS, Nelson JC (1981) Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiat 138: 328–332

    PubMed  CAS  Google Scholar 

  • Cookson J, Silverstone T (1986) The effects of methylamphetamine in mood and appetite in depressed patients: A placebo-controlled study. Int Clin Psychopharmacol 1: 127–133

    Article  PubMed  CAS  Google Scholar 

  • Cooper TB, Juidal SP, Robinson DS, Corcella J (1984) Metabolism of phenelzine in man: Lack of evidence for acetylation pathway. Abstract, collegium international neuro-psychopharmacologium, 14th C.I.N.P. congress, Florence

    Google Scholar 

  • Crane GE (1957) Iproniazid (Marzilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiat Res Rep 8:142–152

    CAS  Google Scholar 

  • Dajas F, Lista A, Barbeito L (1984) High urinary norepinephrine excretion in major depressive orders: Effects of a new type of MAO inhibitor moclobemide, Ro 11–1163). Acta Psychiat Scand 70: 432–437

    Article  PubMed  CAS  Google Scholar 

  • Davidson J, McLeod MMN, Turnbull CD, Miller RD (1981) A comparison of phenelzine and imipramine in depressed inpatients. J Clin Psychiat 42: 10

    Google Scholar 

  • Davidson JRT, Miller RD, Turnbull CD, Sullivan JL (1982) Atypical Depression. Arch Gen Psychiat 39: 527–534

    Article  PubMed  CAS  Google Scholar 

  • Elsworth JD, Glover V, Reynolds GP (1978) Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the “cheese effect“. Psychopharmacology 57: 33–38

    Article  PubMed  CAS  Google Scholar 

  • Feighner JP, Herbstein J, Damlouji N (1985) Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiat 46: 206–209

    CAS  Google Scholar 

  • Georgotas A, Mann J, Friedman E (1981) Platelet monoamine oxidase inhibition as a potential indicator of favourable response to MAOIs in geriatric depressions. Biol Psychiat 16: 997–1001

    PubMed  CAS  Google Scholar 

  • Glover V, Sandler M (1986) Clinical chemistry of monoamine oxidase. Cell Biochem Function 4: 89–97

    Article  CAS  Google Scholar 

  • Gunderson JG, Elliott GR (1985) The interface between borderline personality disorder and affective disorder. Am J Psychiat 142: 277–288

    PubMed  CAS  Google Scholar 

  • Hudson JI, Pope HG, Jonas JM, Yurgelun-Todd D (1985) Treatment of anorexia nervosa with antidepressants. J Clin Psychopharmacol 5: 17– 23

    Google Scholar 

  • Hullett FJ, Bidder TG (1983) Phenelzine plus triiodothyronine combination in a case of refractory depression. J Nerv Ment Dis 171: 318–320

    Article  PubMed  CAS  Google Scholar 

  • Jenike MA (1981) Rapid response of severe obsessive-compulsive disorder to tranylcypromine. Am J Psychiat 138/9: 1249–1250

    PubMed  CAS  Google Scholar 

  • Jenike MA (1984) A case report of successful treatment of dysmorphophobia with tranylcypromine. Am J Psychiat 141: 1463–1464

    PubMed  CAS  Google Scholar 

  • Jenike MA (1985) Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia. Am J Psychiat 142: 763–764

    PubMed  CAS  Google Scholar 

  • Karoum F, Chuang LA, Eisler T (1982) Metabolism of (–) deprenyl to amphetamine and methamphetamine may be responsible for deprenyPs therapeutic benefit: A biochemical assessment, Neurology (NY) 32: 503–509

    CAS  Google Scholar 

  • Kayser A, Robinson DS, Nies A, Howard D (1985) Response to phenelzine among depressed patients with features of hysteroid dysphoria. Am J Psychiat 142: 486–488

    PubMed  CAS  Google Scholar 

  • Kendler KS, Gruenberg AM, Strauss JS (1981) An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia, II. The relationship between schizotypal personality disorder and schizophrenia. Arch Gen Psychiat 38: 982–984

    Article  PubMed  CAS  Google Scholar 

  • Klein DF (1977) Pharmacological treatment and delineation of borderline disorders. In: Hartocollis P (ed) Borderline personality disorders: the concept, the syndrome, the patient. International Universities Press, New York, pp 365–383

    Google Scholar 

  • Kline NS (1985) Clinical experience with iponiazid (Marsilid). J Clin Exp Psychopathol 19 [Suppl] 1: 72–78

    Google Scholar 

  • Korn A, Eichler HG, Gasic S, Raffesberg W, Medizinische I (1984) Moclo-bemide, a new MAO-A inhibitor, does not provoke a “cheese reaction” after ingestion of tyramine containing meals. J Pharm Pharmacol 36 [Workshop Suppl]: 64

    Google Scholar 

  • Krishnan RR, Davidson J, Miller R (1984): MAO inhibitor therapy in trichotillomania associated with depression: Case report. J Clin Psychiat 45: 267–268

    CAS  Google Scholar 

  • Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH (1983) Blood pressure. Effects of phenelzine. J Clin Pharmacol 3: 307–310

    CAS  Google Scholar 

  • Larsen JK, Holm P, Mikkelson PL (1984) Moclobemide and desipramine in the treatment of depression. Acta Psychiat Scand 70: 254–260

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Klein DF (1979) Hysteroid dysphoria. Psychiat Clin Am 2: 555–575

    Google Scholar 

  • Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, Klein DF (1984) Phenelzine v imipramine in atypical depression. Arch Gen Psychiat 41: 669–677

    Article  PubMed  CAS  Google Scholar 

  • Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979) Comparative behavioral effects of chlorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology 62: 123–128

    Article  PubMed  CAS  Google Scholar 

  • Mann JJ, Aarons SF, Frances AJ, Brown RD (1984) Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiat 45: 62–66

    CAS  Google Scholar 

  • McCabe B, Tsuang MT (1982) Dietry consideration in MAO inhibitor regimens. J Clin Psychiat 43: 178–181

    CAS  Google Scholar 

  • Mendis N, Pare CMB, Sandler M, Glover V, Stern GM (1981 a) Is the failure of (–) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology 73: 87–90

    Google Scholar 

  • Mendis N, Pare CMB, Sandler M, Glover V (1981 b) (-)-Deprenyl in the treatment of depression. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors–the state of the art. J Wiley, London

    Google Scholar 

  • Mendlewicz J, Youdim MBH (1980) Antidepressant potentiation of 5-hydroxytryptophan by L-deprenyl in affective illness. J Affect Dis 2: 137–146

    Article  PubMed  CAS  Google Scholar 

  • Mendlewicz J, Youdim MBH (1983) L-Deprenyl, a selective monoamine, oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiat 142: 508–511

    Article  CAS  Google Scholar 

  • Monroe SM, Thase ME, Hersen M, Himmelhock JM, Bellak AS (1985) Life events and the endogenous-nonendogenous distinction in the treatment and posttreatment course of depression. Comp Psychiat 26: 175

    Article  CAS  Google Scholar 

  • Murphy DL, Lipper S, Pickar D, Jimerson D, Cohen RM, Garrick NA, Alter-man IS, Campbell IC (1981) Selective inhibition of monoamine oxidase type A: clinical antidepressant effects and metabolic changes in man. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors–the state of the art. J Wiley, Chichester

    Google Scholar 

  • Murphy DL, Sunderland T, Cohen RM (1984) Monoamine oxidase–inhibiting antidepressants. Psychiat Clin N Am 7: 549–562

    CAS  Google Scholar 

  • Nelson JC, Charney DS (1981) The symptoms of major depressive illness. Am J Psychiat 138: 1–12

    Article  PubMed  CAS  Google Scholar 

  • Nies A, Robinson MD (1981): Comparison of clinical effects of amitripty-line and phenelzine treatment. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors–the state of the art. J Wiley, Chichester

    Google Scholar 

  • Nies A, Robinson DS (1982) Monoamine oxidase inhibitors. In: Paykel ES (ed) Handbook of affective disorders. Churchill Livingstone, Edinburgh

    Google Scholar 

  • Norman TR, Ames D, Burrows GD, Davies B (1985) A controlled study of a specific MAO-A reversible inhibitor (Ro 11–1163) and amtriptyline in depressive illness. J Aff Dis 8: 29–35

    Article  CAS  Google Scholar 

  • Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiat 146: 576–584

    Article  CAS  Google Scholar 

  • Pare CMB, Mousarwi M Al, Sandler M, Glover V (1984) Oral tyramine pressor test in patients receiving a combination of an MAOI and a tricyclic antidepressant. J Pharm Pharmacol 36 [Workshop Suppl]: 65

    Google Scholar 

  • Paykel ES (1985) The clinical interview for depression. Development, reliability and validity. J Aff Dis 9: 85–96

    Article  CAS  Google Scholar 

  • Paykel ES, Parker RR, Penrose RJJ, Rassaby ER (1979) Depressive classification and prediction of response to phenelzine. Br J Psychiat 134: 572–581

    Article  CAS  Google Scholar 

  • Pickar D, Murphy DL, Cohen RM, Campbell IL, Lipper S (1982) Selective and nonselective monoamine oxidase inhibitors. Arch Gen Psychiat 39: 535–540

    Article  PubMed  CAS  Google Scholar 

  • Potter WZ, Murphy DL, Wehr TA, Linnoila M, Goodwin FK (1982) Chlor-gyline. A new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiat 39: 505–510

    Article  PubMed  CAS  Google Scholar 

  • Price LH, Charney DS, Heninger GR (1985) Efficacy of lithium-tranylcypro-mine treatment in refractory depression. Am J Psychiat 142: 619–623

    PubMed  CAS  Google Scholar 

  • Quitkin FM, Liebowitz MR, Stewart JW (1984) L-deprenyl in atypical depressives. Arch Gen Psychiat 41: 777–781

    Article  PubMed  CAS  Google Scholar 

  • Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors. A review of antidepressant effectiveness. Arch Gen Psychiat 35: 749–760

    Article  Google Scholar 

  • Rowan PR, Paykel ES, Parker RR (1982) Phenelzine and amitriptyline: effects on symptoms of neurotic depression. Br J Psychiat 140: 475–483

    Article  CAS  Google Scholar 

  • Schatzberg AF, Rothschild AJ, Gerson B, Lerbinger JE, Schildkraut JJ (1985) Towards a biochemical classification of depressive disorders IX. Br J Psychiat 146: 633–637

    Article  CAS  Google Scholar 

  • Sheehan DV (1984) Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. J Clin Psychiat 45: 29–36

    CAS  Google Scholar 

  • Sheehan DV, Ballenger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiat 37: 51–59

    Article  PubMed  CAS  Google Scholar 

  • Sullivan EA, Shulman KI (1984) Diet and monoamine oxidase inhibitors: A re-examination. Can J Psychiat 29: 707–711

    CAS  Google Scholar 

  • Swinson RP (1984) Response to tranylcypromine and thought stopping in obsessional disorder. Br J Psychiat 144: 425–427

    Article  CAS  Google Scholar 

  • Tipermas A, Gilman HE, Russakoff LM (1984) A case report of leucopenia associated with phenelzine. Am J Psychiat 141: 806–807

    PubMed  CAS  Google Scholar 

  • Tollefson GD (1983) Monoamine oxidase inhibitors: a review. J Clin Psychiat 44: 280–288

    CAS  Google Scholar 

  • Tyrer P, Casey P, Gall J (1983) Relationship between neurosis and personality disorder. Br J Psychiat 142: 404–408

    Article  CAS  Google Scholar 

  • Walsh BT, Stewart JW, Roose SP, Gladis M, Glassman AH (1984) Treatment of bulaemia with phenelzine. A double-blind, placebo-controlled study. Arch Gen Psychiat 41: 1105–1109

    Article  PubMed  CAS  Google Scholar 

  • White K, Simpson G (1984) The combined use of MAOIs and tricyclics. J Clin Psychiat 45: 67–69

    CAS  Google Scholar 

  • Young MA, Sheftner WA, Klerman GL, Andreasen NC, Hirshfeld RMA (1986) The endogenous sub-type of depression: a study of its internal construct validity. Br J Psychiat 148: 257–267

    Article  CAS  Google Scholar 

  • Zahn TP, Insel TR, Murphy DL (1984) Psychophysiological changes during pharmacological treatment of patients with obsessive-compulsive disorder. Br J Psychiat 145: 39–44

    Article  CAS  Google Scholar 

  • Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D (1985) Treatment of hyperactive children with monoamine oxidase inhibitors. Arch Gen Psychiat 42: 962–966

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Cambridge Clinical School, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QQ, UK

    Dr. J. H. Dowson

Authors
  1. Dr. J. H. Dowson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biochemical Pharmacology, University of Uppsala, Sweden

    Lars Oreland

  2. Department of Pharmacology, University of Cambridge, Great Britain

    Brian A. Callingham

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag/Wien

About this chapter

Cite this chapter

Dowson, J.H. (1987). MAO inhibitors in mental disease: their current status. In: Oreland, L., Callingham, B.A. (eds) Monoamine Oxidase Enzymes. Journal of Neural Transmission, vol 23. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8901-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-8901-6_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-81985-2

  • Online ISBN: 978-3-7091-8901-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation